Article

Documenting the location of prostate biopsies with image fusion

Molecular Imaging Program, NCI, NIH, Bethesda, MD, USA.
BJU International (Impact Factor: 3.13). 01/2011; 107(1):53-7. DOI: 10.1111/j.1464-410X.2010.09483.x
Source: PubMed

ABSTRACT OBJECTIVE To develop a system that documents the location of transrectal ultrasonography (TRUS)-guided prostate biopsies by fusing them to MRI scans obtained prior to biopsy, as the actual location of prostate biopsies is rarely known. PATIENTS AND METHODS Fifty patients (median age 61) with a median prostate-specific antigen (PSA) of 5.8 ng/ml underwent 3T endorectal coil MRI prior to biopsy. 3D TRUS images were obtained just prior to standard TRUS-guided 12-core sextant biopsies wherein an electromagnetic positioning device was attached to the needle guide and TRUS probe in order to track the position of each needle pass. The 3D-TRUS image documenting the location of each biopsy was fused electronically to the T2-weighted MRI. Each biopsy needle track was marked on the TRUS images and these were then transposed onto the MRI. Each biopsy site was classified pathologically as positive or negative for cancer and the Gleason score was determined. RESULTS The location of all (n= 605) needle biopsy tracks was successfully documented on the T2-weighted (T2W) MRI. Among 50 patients, 20 had 56 positive cores. At the sites of biopsy, T2W signal was considered 'positive' for cancer (i.e. low in signal intensity) in 34 of 56 sites. CONCLUSION It is feasible to document the location of TRUS-guided prostate biopsies on pre-procedure MRI by fusing the pre-procedure TRUS to an endorectal coil MRI using electromagnetic needle tracking. This procedure may be useful in documenting the location of prior biopsies, improving quality control and thereby avoiding under-sampling of the prostate as well as directing subsequent biopsies to regions of the prostate not previously sampled.

Download full-text

Full-text

Available from: Maria J Merino, Jul 01, 2015
0 Followers
 · 
112 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During transrectal ultrasound (TRUS)-guided prostate biopsies, the actual location of the biopsy site is rarely documented. Here, we demonstrate the capability of TRUS-magnetic resonance imaging (MRI) image fusion to document the biopsy site and correlate biopsy results with multi-parametric MRI findings. Fifty consecutive patients (median age 61 years) with a median prostate-specific antigen (PSA) level of 5.8 ng/ml underwent 12-core TRUS-guided biopsy of the prostate. Pre-procedural T2-weighted magnetic resonance images were fused to TRUS. A disposable needle guide with miniature tracking sensors was attached to the TRUS probe to enable fusion with MRI. Real-time TRUS images during biopsy and the corresponding tracking information were recorded. Each biopsy site was superimposed onto the MRI. Each biopsy site was classified as positive or negative for cancer based on the results of each MRI sequence. Sensitivity, specificity, and receiver operating curve (ROC) area under the curve (AUC) values were calculated for multi-parametric MRI. Gleason scores for each multi-parametric MRI pattern were also evaluated. Six hundred and 5 systemic biopsy cores were analyzed in 50 patients, of whom 20 patients had 56 positive cores. MRI identified 34 of 56 positive cores. Overall, sensitivity, specificity, and ROC area values for multi-parametric MRI were 0.607, 0.727, 0.667, respectively. TRUS-MRI fusion after biopsy can be used to document the location of each biopsy site, which can then be correlated with MRI findings. Based on correlation with tracked biopsies, T2-weighted MRI and apparent diffusion coefficient maps derived from diffusion-weighted MRI are the most sensitive sequences, whereas the addition of delayed contrast enhancement MRI and three-dimensional magnetic resonance spectroscopy demonstrated higher specificity consistent with results obtained using radical prostatectomy specimens.
    Cancer Imaging 03/2011; 11(1):31-6. DOI:10.1102/1470-7330.2011.0007 · 1.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Um die Prostatakarzinomdiagnostik zu optimieren wurde ein neues System für perineale Prostatastanzbiopsien entwickelt, welches eine Echtzeitübertragung von MRT-Daten auf den periinterventionellen Ultraschall gestattet. Hierdurch können suspekte Läsionen gezielt biopsiert werden. Darüber hinaus erlaubt das System, den Entnahmeort jeder einzelnen Biopsie in einer virtuell dreidimensional (3D-)konfigurierten Prostata zu dokumentieren. Material und Methoden Bei 50 konsekutiven Patienten (Alter 67 Jahre, PSA 8,9 ng/ml, Prostatavolumen 51 ml) wurden ein multiparametrisches 3-T-MRT ohne Endorektalspule und anschließend eine stereotaktische Biopsie durchgeführt. Mit Hilfe eines eigens konstruierten TRUS-Schallkopfes, der auf einem speziellen Führungssystem montiert ist, wurde ein 3D-Datensatz der Prostata generiert und mit dem MRT fusioniert. Anschließend wurden suspekte MRT-Befunde gezielt perineal biopsiert. Darüber hinaus wurden nicht auffällige Prostataareale systematisch gestanzt. Ergebnisse Bei 27 von 50 Patienten wurde ein Prostatakarzinom diagnostiziert. Bei zuvor negativ biopsierten Männern erfolgte ein Tumornachweis in 36%. Eine positive Korrelation zwischen MRT-Befund und Histopathologie fand sich bei 36/50 Patienten (72%). Bei hochsuspekten MRT-Läsionen lag die Detektionsrate bei 100% (13/13). Betrachtet man die einzelnen Zylinder aus hochsuspekten Arealen, so waren 40/75 (53%) positiv. Zum Vergleich waren nur 7% der systematischen Stanzen positiv (66/927). Die Abweichung zwischen der geplanten und der tatsächlich biopsierten Position in der Prostata betrug bei 1159 Stanzen im Mittel 1,7 mm. An Nebenwirkungen wurden ein Harnverhalt und ein Hämatom beobachtet. Harnwegsinfekte traten nicht auf. Schlussfolgerungen Perineale stereotaktische Prostatabiopsien unter Zuhilfenahme fusionierter MRT und Ultraschall Datensätze ermöglichen eine effektive Untersuchung von MRT-suspekten Läsionen. Zusätzlich ist es möglich, jede einzelne Biopsie exakt zu dokumentieren. Dadurch können MRT-Daten validiert und Therapien differenziert geplant werden. Die Morbidität des Eingriffs ist minimal.
    Der Urologe 01/2011; 51(1). DOI:10.1007/s00120-011-2707-3 · 0.44 Impact Factor
  • Source
    Image Fusion, 01/2011; , ISBN: 978-953-307-679-9